文献速递帕金森病与运动障碍

抽动症治疗综合系统综述:疗效与风险

Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
PubMed 文献 · Neurology · 2019-01-01

该系统综述遵循美国神经病学学会2011版指南方法学,纳入系统综述和随机对照试验(样本量至少20人,交叉试验至少10人),评估抽动治疗疗效及风险。结果显示综合行为干预对抽动缓解的信心高,氟哌啶醇、利培酮等药物及脑深部刺激信心中等,部分药物信心低,同时存在体重增加、药源性运动障碍等风险。

要点

  • 综合行为干预对抽动缓解的信心高。
  • 氟哌啶醇、利培酮等药物及脑深部刺激可能有效,信心中等。
  • 治疗需权衡疗效与风险,如体重增加、药源性运动障碍。

核心结论

  • 有证据支持多种药物、行为及神经刺激干预对抽动治疗有效。
  • 制定治疗推荐时需同时考虑干预措施的疗效和危害。

研究设计与样本

  • 遵循美国神经病学学会2011版指南制定方法学。
  • 纳入系统综述和随机对照试验(样本量至少20人,交叉试验至少10人),神经刺激试验无最小样本量要求。
  • 纳入评估药物不良反应的队列研究或病例系列。

主要发现

  • 综合行为干预比心理教育和支持治疗更可能减少抽动,信心高。
  • 氟哌啶醇、利培酮、阿立哌唑、硫必利、可乐定、A型肉毒毒素注射、5-ling颗粒、宁动颗粒及苍白球脑深部刺激可能比安慰剂更可能减少抽动,信心中等。
  • 匹莫齐特、齐拉西酮、甲氧氯普胺、胍法辛、托吡酯及四氢大麻酚可能比安慰剂更可能减少抽动,信心低。
  • 有证据显示治疗相关危害,包括体重增加、药源性运动障碍、催乳素水平升高、镇静及对心率、血压和心电图的影响。

临床怎么用

  • 临床决策应综合考虑干预措施的疗效证据等级和潜在危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically evaluate the efficacy of treatments for tics and the risks associated with their use. METHODS: This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology's guideline development process manual. We included systematic reviews and randomized controlled trials on the treatment of tics that included at least 20 participants (10 participants if a crossover trial), except for neurostimulation trials, for which no minimum sample size was required. To obtain additional information on drug safety, we included cohort studies or case series that specifically evaluated adverse drug effects in individuals with tics. RESULTS: There was high confidence that the Comprehensive Behavioral Intervention for Tics was more likely than psychoeducation and supportive therapy to reduce tics. There was moderate confidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinumtoxinA injections, 5-ling granule, Ningdong granule, and deep brain stimulation of the globus pallidus were probably more likely than placebo to reduce tics. There was low confidence that pimozide, ziprasidone, metoclopramide, guanfacine, topiramate, and tetrahydrocannabinol were possibly more likely than placebo to reduce tics. Evidence of harm associated with various treatments was also demonstrated, including weight gain, drug-induced movement disorders, elevated prolactin levels, sedation, and effects on heart rate, blood pressure, and ECGs. CONCLUSIONS: There is evidence to support the efficacy of various medical, behavioral, and neurostimulation interventions for the treatment of tics. Both the efficacy and harms associated with interventions must be considered in making treatment recommendations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019. PMID: 31061209. doi:10.1212/WNL.0000000000007467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。